Corporate Participation 2020
During the 2021 NBTE annual meeting, Corporate participation is intended to connect companies with PhD-students/postdocs to potentially facilitate their next phase of their career. Representative of succesfull dutch companies will shared their experience during an informal discussion with young researchers.
Further information on the attending companies and representatives can be found below.
We revolutionize microparticle production. Most products in cosmetics, life sciences, and pharmaceutical markets are nowadays based on microparticles. IamFluidics leverages innovative production processes to engineer superb, sustainable, and appealing products based on high-quality microparticles.
Tom Kamperman, Phd
Co-founder & CTO
Research Fellow in Medicine at Brigham and Women’s Hospital / Harvard Medical School (USA)
Tom is an entrepreneurial biomedical engineer with a strong background in microfluidics, tissue engineering, and enabling (micro)technologies. He has over eight years of experience with the development of microfluidic systems for life science applications and in particular microencapsulation. He has been working at various internationally recognized institutes including the Max-Planck Institute in Muenster (DE), the MESA+ Institute for Nanotechnology (NL), the Technical Medical Centre (NL), and the Division of Engineering in Medicine at Harvard Medical School (USA). Tom received the ‘Overijssel PhD award’, ‘NBTE PhD thesis award’, and ‘DutchBiophysics BIOPM thesis award’ for his PhD thesis titled ‘Microgel Technology to Advance Modular Tissue Engineering’. In 2019, he was elected “European Innovator Under 35” by MIT Technology Review. Tom is co-inventor of the ‘in-air microfluidics’ technology and co-founder of the company IamFluidics BV, where he is responsible for technical management and product development. Tom is currently also affiliated as a Research Fellow in Medicine at Brigham and Women’s Hospital / Harvard Medical School (USA), where he is working on single cell encapsulation to protect cells during 3D bioprinting.
Kuros Biosciences (SIX:KURN) develops innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Kuros Biosciences aims to deliver decreased complications, advanced functional rehabilitation and to eliminate non-unions for spine surgeons and their patients. With more than 150 years of combined research experience, Kuros Biosciences are well-established as leaders in orthobiologics. Our focus is on revolutionizing this field by developing bone grafts that deliver both targeted and controlled bone healing. Kuros recently launched MagnetOs, a unique calcium phosphate bone graft with submicron surface topography, that harnesses the power of osteoimmunology to deliver uniform, solid and stable spinal fusions. This technology has an osteoinductive claim in Europe. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.
Florence Barrère-de Groot, PhD
Head of Development
Florence is graduated in Material Science from the University Paul Sabatier in Toulouse (France), and moved to The Netherlands in 1998 to start her PhD on biomimetic calcium phosphate coatings for bone regeneration at University of Twente (The Netherlands). She obtained her PhD degree in 2003. She has over 15 years industrial experience in bone biomaterials both in The Netherlands and Switzerland. She leads the development of new products for bone repair at Kuros Biosciences BV. Her responsibilities lie in the creation and market authorization of innovative bone graft for human use. Dr. de Groot patented formulations and developed GMP processes for bone graft substitutes used in European and US Hospitals. She led projects for the research, discovery of nanostructured bone grafts from bench testing to clinical trials of for spine, orthopaedic, dental and craniomaxillofacial use. As R&D activities, she coordinated and collaborated in numeral international translational programs with academia, hospitals and companies. She has published more than 25 journal papers on bone grafting materials, book chapters and a number of conference publications.
The mission of Avania is to navigate medical technologies to market effectively and efficiently, with expertise and integrity. Our vision is to be a trusted global partner in the evolution of medical technology from innovation to commercialization to improve patient health and wellbeing.
At Avania, we have extensive expertise and understanding of the various components involved in all clinical investigation pathways. We will work with medical device start-ups and large manufacturers to advise them in the clinical, regulatory (EC), data management and medical writing services as proficiently as possible. We are specialized in and understand medical devices. We can help companies navigate through product development with regulatory and clinical strategies as well as clinical investigation execution and post-market requirements – something most other CROs cannot or simply do not offer in this arena.
Niels van Tienen
Director Clinical Operations EU
Niels has a background in sports and in physical education, and was trained as movement scientist (bewegingswetenschapper) at the University of Maastricht. After an extensive training program at Medtronic in the Netherlands and in Minneapolis (US), almost 15 years ago he started his career at Avania (at that time Factory-CRO for Medical Devices). As Director of Clinical Operations, he is responsible for the teams that set up and supervise clinical research in Europe and the United States, prepare Clinical Evaluation Reports for notified bodies and set up databases for clinical research. Niels regularly presents these activities at conferences and workshops.
CytoSMART is an innovator in kinetic live-cell imaging. Combining compact and fast imaging hardware with powerful image analysis algorithms supported by cloud computing. Automation in time-lapse microscopy and image based cell counting to generate high-quality and robust data. Our team of engineers continue to develop and optimize the image analysis and data storage capacities linked to our systems, making sure that data-sets are easily processed, stored and kept securely in an online environment. We want to enable research that builds on large data-sets and is conveniently communicated.
Inge Thijssen van Loosdregt, PhD
Field Application Engineer
Inge is a Field Application Engineer at CytoSMART with a background in life sciences. She has obtained her Ph.D. in soft tissue engineering and mechanobiology at the Eindhoven University of Technology. Inge’s Ph.D. work focused on understanding the forces generated by fibroblasts in order to eventually optimize the design of tissue-engineered heart valves. As a Field Application Engineering, she tests CytoSMART's devices in the lab and works with R&D to keep optimizing and validating the devices in order to fulfill the needs of life science researchers.